NCT04555824View on ClinicalTrials.gov

A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

February 20, 2018

Study Completion Date

June 20, 2018

Conditions
Healthy
Interventions
DRUG

Recombinant Human Thymosin β4

Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

OTHER

Placebo

Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.

Trial Locations (1)

Unknown

Beijing Shijitan Hospital, Beijing

All Listed Sponsors
lead

Beijing Northland Biotech. Co., Ltd.

INDUSTRY

NCT04555824 - A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers | Biotech Hunter | Biotech Hunter